Although there has been considerable buzz around the recent U.S. Food and Drug Administration (FDA) acceptance of Eli Lilly’s monoclonal antibody bamlanivimab (LYCoV555) for emergency use authorization (EUA) targeting COVID-19, the Infectious Diseases Society of America (IDSA) recommended against the routine use of this novel drug. Although the group of physicians is open to use if the patient has a thorough understanding of the benefits as well as the risks, the strong statement certainly sends a message. Note, TrialSite appeared to be the only media platform to report on the total price the U.S. government was paying Lilly for this highly experimental drug: at $1,250 per via for a total of $375 million for the first purchase of 300,000 vials with an option (at same price) for 650,000 vials worth up to $1.2 billion in sales.
TrialSite follows with a brief breakdown of this recent position written by Marie Rosenthal IDSA published in Infectious Disease Special Edition (IDSE).
What is bamlanivimab?
This monoclonal antibody originally developed by University of British Columbia spinoff AbCellera in collaboration with National Institute of Allergy and Infecti...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).